

**GYNECOLOGY DISEASE SITE COMMITTEE**

**MOLECULAR STRATIFICATION OF GYNAECOLOGICAL MALIGNANCIES: EMERGING CLINICAL RESEARCH TRENDS IN ENDOMETRIAL AND VULVAR CARCINOMA WORKSHOP**

CHELSEA HOTEL, TORONTO, ON  
 ROOM: CHURCHILL B  
 SATURDAY APRIL 29, 2023 8:30– 10:30 EST

**CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.*

**Learning Objectives:**

- To demonstrate the companion biomarker interpretation of the molecular classification of endometrial cancer.
- To review the common interpretive pitfalls of biomarkers for molecular endometrial carcinoma.
- To identify the common barriers to biomarker integration and their potential solutions
- To illustrate the defining key pathology parameters, including molecular classification, that define eligibility for EN.10 TAPER/RAINBO blue and EN.11 RAINBO green trials.
- To identify the etiology in the classification of vulvar squamous carcinoma and the companion biomarkers.
- To combine the usage of vulvar squamous carcinoma biomarker ordering, interpretation, and reporting in clinical practice and eligibility for enrollment of VU.2 STRIVE trial and its study arms.

<b>8:30-8:35 am</b>	<b>Overview of endometrial cancer landscape</b>	<b>Jessica McAlpine</b>
<b>8:35-8:40 am</b>	<b>EN.10 trial review</b>	<b>Kathy Han</b>
<b>8:40-8:45 am</b>	<b>EN. 11 trial review</b>	<b>Stephen Welch</b>
<b>8:45-9:20 am</b>	<b>Pathology and molecular Inclusion</b>	<b>Mary Kinloch/Anjelica Hodgson</b>
<b>9:20-9:30 am</b>	<b>Review of Survey Results</b>	<b>Mary Kinloch/Anjelica Hodgson</b>
<b>9:30-9:45 am</b>	<b>Q&amp;A</b>	
<b>9:45-9:50 am</b>	<b>Vulvar cancer landscape and VU.2 trial review</b>	<b>Amy Jamieson</b>
<b>9:50-10:20 am</b>	<b>VU.2 pathology eligibility</b>	<b>Lien Hoang</b>
<b>10:20-10:30 am</b>	<b>Q&amp;A</b>	

